Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK

Ursodeoxycholic acid (UDCA), first identified in bear bile, was widely used in cholestatic liver diseases. Our previous studies have suggested UDCA may exert favorable influence on hepatic steatosis. However, the molecular mechanism remains elusive. Given the role of autophagy and apoptosis dysregul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2020-08, Vol.529 (3), p.834-838
Hauptverfasser:	Wu, Pengbo, Zhao, Jinbo, Guo, Yitian, Yu, Yuanjie, Wu, Xiaoman, Xiao, Hongmiao
Format:	Artikel
Sprache:	eng
Schlagworte:	AMP-Activated Protein Kinases - metabolism AMPK Animals Apoptosis Apoptosis - drug effects Autophagy Autophagy - drug effects Enzyme Activation - drug effects Enzyme Activators - therapeutic use Male Non-alcoholic fatty liver disease Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - pathology Rats, Sprague-Dawley Ursodeoxycholic acid Ursodeoxycholic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!